CTLA4 and neoplasm: We have previously demonstrated the ability of FLIM to assess the immune response to tumor development [20] and to the anti-CTLA-4 therapy [38] by the measurements of the fluorescence lifetime of NAD(P)H in fresh lymphoid tissue.